Investment Bank Downgrades Orchid Stock After Firm Cut 05 Revenue Projection | GenomeWeb

NEW YORK, March 10 (GenomeWeb News) - Investment bank Caris & Company downgraded Orchid Cellmark stock to "average" from "above average" yesterday after the company cut its 2005 revenue projections.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.